845 results match your criteria Pityriasis Rubra Pilaris


Regulation and dysregulation of CARD14 signalling and its physiological consequences in inflammatory skin disease.

Authors:
Mark Mellett

Cell Immunol 2020 Jun 13;354:104147. Epub 2020 Jun 13.

Department of Dermatology, University Hospital of Zürich, Zürich, Switzerland. Electronic address:

CARD14 is a scaffold molecule predominantly expressed in keratinocytes and genetic variants in the CARD14 gene confer an increased risk of inflammatory skin disease. Due to its association with common skin diseases psoriasis and atopic dermatitis, the biological function of CARD14 is of relevant interest to human health. CARD14 recruits BCL10 and MALT1 to form the CARD-BCL10-MALT1 complex, which modulates NF-κB and MAPK signalling pathways, yet little is known about how CARD14 is regulated or activated in the context of the innate immune response and in chronic inflammation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cellimm.2020.104147DOI Listing

Erythema gyratum repens-like eruption after anti-IL-17 therapy of pityriasis rubra pilaris.

J Eur Acad Dermatol Venereol 2020 Jun 24. Epub 2020 Jun 24.

Department of Dermatology, Inselspital, Bern University Hospital, Bern, Switzerland.

Pityriasis rubra pilaris (PRP) is a rare inflammatory skin disease characterized by wide-spread follicular hyperkeratosis and erythrosquamous plaques with demarcated islands of sparing. Spontaneous remissions can occur, but PRP often shows a prolonged and therapy-resistant course. Although the pathogenesis remains incompletely understood, the Th17 axis is implicated in driving cutaneous inflammation in PRP. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/jdv.16785DOI Listing

Erythroderma: a prospective study of 309 patients followed for 12 years in a tertiary center.

Sci Rep 2020 Jun 17;10(1):9774. Epub 2020 Jun 17.

Division of Clinical Dermatology, Hospital das Clínicas, University of São Paulo Medical School, São Paulo, Brazil.

Erythroderma is characterized by erythema and scaling affecting more than 80% of the body surface area. It is potentially life-threatening, and diagnosis of the underlying disease is a challenge. Despite laboratory improvements, many cases remain idiopathic. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41598-020-66040-7DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7300014PMC

Paraneoplastic Pityriasis Rubra Pilaris Heralding Onset of New Hematologic Malignancy.

Am J Hematol 2020 Jun 5. Epub 2020 Jun 5.

Harvard Medical School, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.25897DOI Listing

Influence of COVID-19 pandemic on hospitalizations at the tertiary dermatology department in south-west Poland.

Dermatol Ther 2020 Jun 1. Epub 2020 Jun 1.

Department of Dermatology, Venereology and Allergology, Wroclaw Medical University. Wroclaw, Poland.

New virus SARS-Cov-2 infection has spread over the world affecting all daily activities, including functioning of health services. Due to pandemic many hospitals were ordered to re-organize their work. The aim of the current report was to evaluate the influence of COVID-19 pandemic on the hospitalizations at the tertiary dermatology department in south-west Poland. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/dth.13738DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7300546PMC

"Successful treatment of resistant pityriasis rubra pilaris with ixekizumab".

Dermatol Ther 2020 May 22. Epub 2020 May 22.

Department of Dermatology, Hospital Universitario 12 de Octubre, I+12 Research Institute, Universidad Complutense, Madrid, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/dth.13644DOI Listing

Refractory classic juvenile pityriasis rubra pilaris successfully treated with a combination of etanercept and methotrexate.

Dermatol Ther 2020 May 28;33(3):e13431. Epub 2020 Apr 28.

Department of Dermatology, Dermatology Hospital, Southern Medical University, Guangzhou, China.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/dth.13431DOI Listing

Evaluation of Ixekizumab Treatment for Patients With Pityriasis Rubra Pilaris: A Single-Arm Trial.

JAMA Dermatol 2020 Apr 15. Epub 2020 Apr 15.

Department of Dermatology, Oregon Health & Science University, Portland, Oregon.

Importance: Pityriasis rubra pilaris is a rare and disabling cutaneous disease that is frequently recalcitrant to conventional therapies and appears to involve interleukin (IL)-17 overexpression.

Objective: To investigate the clinical response and safety of ixekizumab in treating pityriasis rubra pilaris.

Design, Setting, And Participants: Single-arm, investigator-initiated trial conducted in adult patients with moderate to severe pityriasis rubra pilaris at a single-center academic university from June 2018 to January 2020. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/jamadermatol.2020.0932DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7160757PMC

Apremilast-associated drug reaction with eosinophilia and systemic symptoms.

JAAD Case Rep 2020 Apr 25;6(4):302-304. Epub 2020 Mar 25.

Department of Dermatology, Henry Ford Health System, Detroit, Michigan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jdcr.2020.01.013DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7109365PMC

Familial pityriasis rubra pilaris successfully treated with brodalumab.

Int J Dermatol 2020 Jul 23;59(7):885-887. Epub 2020 Mar 23.

Centre for the Study and Treatment of Psoriasis at the Department of Clinical Dermatology, San Gallicano Dermatological Institute, IRCCS, Rome, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ijd.14857DOI Listing

Dermatoscopy in life-threatening and severe acute rashes.

Clin Dermatol 2020 Jan - Feb;38(1):113-121. Epub 2019 Nov 11.

Institute of Dermatology, Santa Maria della Misericordia University Hospital, Udine, Italy.

A prompt recognition of life-threatening and severe acute rashes is of utmost importance to start an appropriate therapy as soon as possible. Consequently, clinicians often must rely only on clinical data to make a diagnosis because some diagnostic procedures may take a relatively long time to be performed (eg, histologic examination, microbiologic tests). In this scenario, dermatoscopy may be useful as an auxiliary tool to support the diagnosis by highlighting subclinical features. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clindermatol.2019.10.013DOI Listing
November 2019

[Pityriasis rubra pilaris : Successful treatment with ixekizumab].

Authors:
D Kohn T Wetzig

Hautarzt 2020 Mar 17. Epub 2020 Mar 17.

Klinik für Dermatologie, Dermatochirurgie und Allergologie, Asklepios Klinik Weißenfels, Naumburger Str. 76, 06667, Weißenfels, Deutschland.

Pityriasis rubra pilaris is a rare papulosquamous chronic skin disease. The disease often exists for years and is difficult to treat. Not only is it clinically similar to psoriasis vulgaris, but both diseases also have a similar cytokine profile. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00105-020-04575-6DOI Listing

Pulsed dye laser as an adjunctive treatment for therapy resistant pityriasis rubra pilaris.

J Am Acad Dermatol 2020 Mar 11. Epub 2020 Mar 11.

Department of Dermatology, West Virginia University, Morgantown, WV, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jaad.2020.02.075DOI Listing

Autoinflammatory Keratinization Diseases (AiKDs): Expansion of Disorders to Be Included.

Authors:
Masashi Akiyama

Front Immunol 2020 21;11:280. Epub 2020 Feb 21.

Department of Dermatology, Nagoya University Graduate School of Medicine, Nagoya, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fimmu.2020.00280DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7046805PMC
February 2020

Off-label dermatologic uses of IL-17 inhibitors.

J Dermatolog Treat 2020 Mar 9:1-7. Epub 2020 Mar 9.

Department of Dermatology, Loma Linda University, Loma Linda, CA, USA.

IL-17 inhibitors, including secukinumab, brodalumab, and ixekizumab, have been U.S. Food and Drug Administration (FDA) approved for the treatment of psoriasis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/09546634.2020.1737638DOI Listing

Treatment modalities for pityriasis rubra pilaris subtypes: a review.

J Dermatolog Treat 2020 Mar 30:1-2. Epub 2020 Mar 30.

Department of Dermatology, St Vincent's Hospital Melbourne, Fitzroy, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/09546634.2020.1729954DOI Listing

Acral pityriasis rubra pilaris.

CMAJ 2020 02;192(5):E118

Department of Medicine, Cumming School of Medicine, University of Calgary, Calgary, Alta.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1503/cmaj.190961DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7004218PMC
February 2020

Hyperkeratotic Skin Adverse Events Induced by Anticancer Treatments: A Comprehensive Review.

Drug Saf 2020 May;43(5):395-408

Oncodermatology, Institut Claudius REGAUD and Institut Universitaire du Cancer Toulouse Oncopole, 1 avenue Irène Joliot-Curie 31059, Toulouse Cedex 9, France.

Hyperkeratotic skin adverse events are a group of toxic effects, characterized by the disruption of epidermal homeostasis and interaction with keratinocyte proliferation/differentiation or keratinocyte survival, and frequently reported with systemic anticancer treatments. These types of reactions include hand-foot skin reaction or palmoplantar keratoderma, induced psoriasis, keratosis pilaris-like or pityriasis rubra pilaris-like rashes, Grover's disease, and contact hyperkeratosis. Cutaneous squamoproliferative lesions are also described because of the presence of abnormal keratinocyte proliferation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40264-020-00907-6DOI Listing

Coexistence of Anogenital Psoriasis and Genital Warts - Is There an Optimal Treatment?

Acta Dermatovenerol Croat 2019 Dec;27(4):270-272

Assoc. Prof. Suzana Ljubojević Hadžavdić, MD, PhD, Department of Dermatology and Venereology, Zagreb University Hospital Center, University of Zagreb School of Medicine, Šalata 4, 10000 Zagreb, Croatia;

The prevalence of psoriasis is 2% of the world's population (1). Inverse psoriasis is characterized by the development of erythematous shiny plaques at intertriginous areas of the body. The prevalence of only anogenital involvement appears to be low, but involvement of the anogenital area together with other areas is found in up to 45% of patients with psoriasis (2). Read More

View Article

Download full-text PDF

Source
December 2019

The color of skin: orange diseases of the skin, nails, and mucosa.

Clin Dermatol 2019 Sep - Oct;37(5):520-527. Epub 2019 Jul 18.

Department of Dermatology, University of Illinois at Chicago College of Medicine, Chicago, Illinois, USA. Electronic address:

Cutaneous disease can present with lesions of all colors of the visible spectrum. Lesions of the skin, nail, and mucous membranes with an orange color can be due to a variety of etiologies. The conditions may appear as purely orange, yellow-orange, red-orange, tan, or brown with an orange hue. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clindermatol.2019.07.014DOI Listing

Pityriasis rubra pilaris-like graft-vs-host disease following allogeneic stem cell transplant in two patients.

Clin Case Rep 2019 Dec 14;7(12):2491-2494. Epub 2019 Nov 14.

Department of Dermatology Stanford University Medical Center Stanford California.

Chronic cutaneous graft-vs-host disease (GVHD) has several atypical variants. We describe two cases of GVHD with clinical and histopathologic features of pityriasis rubra pilaris (PRP), which responded to additional immunosuppression. Recognition of this newly described PRP-like clinical presentation of GVHD may prompt early consideration of additional steroid-sparing therapies. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ccr3.2458DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6935619PMC
December 2019

A novel mutation of ABHD5 gene in a Chanarin Dorfman patient with unusual dermatological findings.

Lipids Health Dis 2019 Dec 28;18(1):232. Epub 2019 Dec 28.

Laboratory of Cellular Biochemistry and Molecular Biology, CRIBENS, Catholic University of the Sacred Heart, pz Buonarroti 30, 20145, Milan, Italy.

Background: Chanarin Dorfman Syndrome (CDS) is a rare autosomal recessive disorder characterized by the multisytemic accumulation of neutral lipids inside the cytoplasmic lipid droplets. This condition is caused by mutations in the abhydrolase domain containing 5 gene (ABHD5). In CDS the skin involvement is the prevalent and always observed clinical feature, consisting of a non-bullous congenital ichthyosiform erythroderma (NCIE). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12944-019-1181-6DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6935165PMC
December 2019

Pityriasis rubra pilaris as a systemic disease.

Clin Dermatol 2019 Nov - Dec;37(6):657-662. Epub 2019 Jul 31.

Department of Dermatology and Venereology, Acibadem City Clinic Tokuda Hospital, Sofia, Bulgaria. Electronic address:

Pityriasis rubra pilaris (PRP) is a rare inflammatory skin disorder of unknown etiology, initially described in 1835. It is characterized by keratotic follicular papules, well-demarcated salmon-colored erythematous scaly plaques interspersed with distinct islands of uninvolved skin, and palmoplantar keratoderma. Is PRP a systemic disease? Skin is mainly affected in PRP. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clindermatol.2019.07.030DOI Listing

Successful treatment of Pityriasis rubra pilaris with brodalumab.

Australas J Dermatol 2020 May 18;61(2):e249-e251. Epub 2019 Dec 18.

Dermatology Unit, Department of Mentals and Physical Health and Preventive medicine, University of Campania Luigi Vanvitelli Naples, Napoli, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ajd.13215DOI Listing

Histopathologic findings characteristic of CARD14-associated papulosquamous eruption.

J Cutan Pathol 2020 May 26;47(5):425-430. Epub 2019 Dec 26.

Department of Dermatology, Yale University, New Haven, Connecticut.

Background: Pathogenic mutations in caspase recruitment domain-containing protein 14 (CARD14) lead to CARD14-associated papulosquamous eruption, which shares clinicopathologic findings with psoriasis and pityriasis rubra pilaris. We aimed to describe distinguishing histopathologic features of CARD14-associated papulosquamous eruption.

Methods: This retrospective study examined the histopathologic features of specimens from patients with confirmed CARD14-associated papulosquamous eruption and adult patients with plaque psoriasis and pityriasis rubra pilaris. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/cup.13633DOI Listing

[Atypical Sézary syndrome in a young subject].

Ann Dermatol Venereol 2020 May 2;147(5):355-360. Epub 2019 Dec 2.

Service de dermatologie, université catholique, hôpital Saint-Vincent de Paul, boulevard de Belfort, 59000 Lille, France.

Introduction: Sézary syndrome accounts for 5% of cutaneous T-cell lymphomas, with mean age of onset of 60 years. Erythroderma associated with palmoplantar keratoderma and lymphadenopathy is the usual clinical presentation, but the disease has potentially confusing polymorphic clinical features.

Patients And Methods: We report the case of a 27-year-old patient with no notable disease history, presenting generalized non-pruritic dermatosis for 3 months, with erythema and papules, and follicular distribution, localized to the limbs, the trunk and the face. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.annder.2019.10.023DOI Listing
May 2020
5 Reads

Paraneoplastic pityriasis rubra pilaris in association with prostate carcinoma: A case report and literature review.

Exp Ther Med 2019 Dec 7;18(6):5052-5055. Epub 2019 Nov 7.

CMI Dermamed, 530540 Târgu Mureş, Romania.

Pityriasis rubra pilaris (PRP) is a chronic papulosquamous disorder of unknown etiology, characterized by reddish orange scaly plaques, islands of sparing, palmoplantar keratoderma, and keratotic follicular papules. The disease can be acquired or inherited, being divided into 5 categories: classic adult type, atypical adult type, classic juvenile type, circumscribed juvenile type, and atypical juvenile type. More recently, an HIV-associated type has been added to this classification. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3892/etm.2019.8169DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6880360PMC
December 2019

Treatment of pityriasis rubra pilaris type I: a systematic review.

Eur J Dermatol 2019 Oct;29(5):524-537

Department of Dermatology, University Hospital, JenaGermany.

Pityriasis rubra pilaris (PRP) is an uncommon papulosquamous inflammatory disease of the skin, which may progress to erythroderma. The diagnosis is based on both clinical and histopathological findings. There are numerous treatment options in the literature, but often reported as unsuccessful. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1684/ejd.2019.3641DOI Listing
October 2019

Acantholytic pityriasis rubra pilaris associated with topical use of imiquimod 5%: case report and literature review.

An Bras Dermatol 2020 Jan - Feb;95(1):63-66. Epub 2019 Nov 23.

Department of Anatomical Pathology, Universidade Estadual de Campinas, Campinas, SP, Brazil.

Topical use of immune response modifiers, such as imiquimod, has increased in dermatology. Although its topical use is well tolerated, it may be associated with exacerbations of generalized cutaneous inflammatory diseases, possibly through the systemic circulation of pro-inflammatory cytokines. This report describes a case of development of pityriasis rubra pilaris, a rare erythematous-papulosquamous dermatosis, in a woman aged 60 years during treatment with imiquimod 5% cream for actinic keratosis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.abd.2019.01.009DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7058836PMC

Familial pityriasis rubra pilaris in a Chinese family caused by a novel mutation in CARD14 gene.

Indian J Dermatol Venereol Leprol 2020 Jan-Feb;86(1):81-84

Xinhua College, Sun Yat-sen University; Guangzhou Institute of Obstetrics and Gynecology, Key Laboratory for Major Obstetric Diseases of Guangdong Province, Key Laboratory of Reproduction and Genetics of Guangdong Higher Education Institutes, The Third Affiliated Hospital of Guangzhou Medical University, Guangzhou 510150, Guangdong, China.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4103/ijdvl.IJDVL_9_18DOI Listing
November 2019
1.325 Impact Factor

Use of Biologics in Pityriasis Rubra Pilaris Refractory to First-Line Systemic Therapy: A Systematic Review [Formula: see text].

J Cutan Med Surg 2020 Jan/Feb;24(1):73-78. Epub 2019 Nov 6.

12366 210484 Division of Dermatology, Department of Medicine, University of Toronto, ON, Canada.

Pityriasis rubra pilaris (PRP) is an uncommon, inflammatory, papulosquamous skin disease. Treatment of PRP is challenging as the disease is often refractory to conventional therapies, such as retinoids and methotrexate. There has been an increasing number of studies reporting the successful use of biologic therapy in patients with PRP; however, the data on the efficacy and safety are limited. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1203475419887731DOI Listing
November 2019
6 Reads

Erythroderma secondary to pityriasis rubra pilaris.

Indian J Med Res 2019 08;150(2):206-207

Department of Dermatology, Hospital Regional Universitario de Málaga, Málaga, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4103/ijmr.IJMR_294_18DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6829778PMC

Erythroderma in the course of pityriasis rubra pilaris in a 7-year-old female.

Postepy Dermatol Alergol 2019 Aug 30;36(4):501-503. Epub 2019 Aug 30.

Department of Dermatology and Venereology, Stefan Zeromski Municipal Hospital, Krakow, Poland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.5114/ada.2019.87456DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6791152PMC
August 2019
1 Read

Treatment of Pityriasis Rubra Pilaris With Guselkumab.

JAMA Dermatol 2019 Oct 2. Epub 2019 Oct 2.

Department of Dermatology and Allergy, Technical University of Munich, Munich, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/jamadermatol.2019.2774DOI Listing
October 2019
2 Reads

Pityriasis rubra pilaris-like eruption in the setting of transient acantholytic dermatosis.

JAAD Case Rep 2019 Aug 5;5(8):733-735. Epub 2019 Aug 5.

Department of Dermatology, University of Iowa Hospitals and Clinics, Iowa City, Iowa.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jdcr.2019.06.025DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6698694PMC
August 2019
2 Reads

Learning From Success and Failure: Biologics for Non-approved Skin Diseases.

Front Immunol 2019 8;10:1918. Epub 2019 Aug 8.

Department of Dermatology, Ghent University Hospital, Ghent, Belgium.

The impressive potential of biologics has been demonstrated in psoriasis, hidradenitis suppurativa, and urticaria. Numerous biologicals are entering the field for a restricted number of skin disorders. Off-label use of biologics in other recalcitrant skin diseases has increased. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fimmu.2019.01918DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6694799PMC
August 2019
16 Reads

Patient experiences with biologics and apremilast in pityriasis rubra pilaris: A patient survey.

Dermatol Ther 2019 09 18;32(5):e13060. Epub 2019 Aug 18.

Department of Dermatology, University of Southern California, Los Angeles, California.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/dth.13060DOI Listing
September 2019
2 Reads

Efficacy of methotrexate as anti-inflammatory and anti-proliferative drug in dermatology: Three case reports.

Exp Ther Med 2019 Aug 19;18(2):905-910. Epub 2019 Apr 19.

Faculty of Medicine, 'Carol Davila' University of Medicine and Pharmacy, 050474 Bucharest, Romania.

Methotrexate (MTX) is a folic acid analog with anti-proliferative (anti-neoplastic, cytotoxic), immunosuppressive and anti-inflammatory properties, which has been used in the treatment of various cutaneous disorders, such as psoriasis, keratoacanthoma, pityriasis rubra pilaris, atopic dermatitis, mycosis fungoides, bullous skin diseases, systemic sclerosis, morphea, lupus erythematosus, dermatomyositis and crusted scabies. Inhibition of cell proliferation is explained through its role in blocking DNA/RNA synthesis, by inhibiting dihydrofolate reductase, necessary for the production of pyrimidine and purine nucleotides. An anticancer effect can be related to α-oxoaldehyde metabolism (MTX increases methylglyoxal levels). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3892/etm.2019.7511DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6639959PMC
August 2019
12 Reads

Dermoscopy of Erythrodermic Pityriasis Rubra Pilaris.

Indian Dermatol Online J 2019 Jul-Aug;10(4):500-501

Department of Histopathology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4103/idoj.IDOJ_156_18DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6615401PMC
July 2019
10 Reads

Koebner Phenomenon in Classic Juvenile Onset Pityriasis Rubra Pilaris.

Indian Dermatol Online J 2019 Jul-Aug;10(4):469-470

Department of Pathology, IGMC, Shimla, Himachal Pradesh, India.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4103/idoj.IDOJ_363_18DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6615387PMC
July 2019
4 Reads

Whole exome sequencing approach to childhood onset familial erythrodermic psoriasis unravels a novel mutation of CARD14 requiring unusual high doses of ustekinumab.

Pediatr Rheumatol Online J 2019 Jul 8;17(1):38. Epub 2019 Jul 8.

Centro Malattie Autoinfiammatorie e Immunodeficienze- Clinica Pediatrica e Reumatologia, IRCCS Giannina Gaslini, Via Gaslini 5, 16147, Genova, Italy.

Background: Autosomal dominant gain of function mutations in caspase recruitment domain family member 14 (CARD14) is a rare condition associated with plaque-type psoriasis, generalized pustular psoriasis, palmoplantar pustular psoriasis and pityriasis rubra pilaris. Recently, a new CARD14 -associated phenotype defined as CAPE (CARD14-associated papulosquamous eruption) with clinical features of both psoriasis and pityriasis rubra pilaris was reported. We describe a family carrying a novel heterozygous mutation in CARD14 gene, with childhood-onset erythrodermic psoriasis requiring an unusual extremely high dose (up to 2 mg/kg every 8 weeks) of ustekinumab to achieve disease remission. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12969-019-0336-3DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6615224PMC
July 2019
7 Reads

[Paraneoplastic skin diseases].

Internist (Berl) 2019 Aug;60(8):775-782

Hautklinik und Hauttumorzentrum Rheinpfalz, Klinikum der Stadt Ludwigshafen, Bremserstraße 79, 67063, Ludwigshafen am Rhein, Deutschland.

Various specific skin alterations can occur in patients with malignant diseases. If these skin diseases occur as associated symptoms of a malignant process, they are called paraneoplastic. In this overview, obligate and frequent facultative paraneoplastic skin diseases are assigned according to the triggering type of malignancy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00108-019-0636-1DOI Listing
August 2019
9 Reads

Rapid response of pityriasis rubra pilaris with psoriasis overlap to secukinumab.

Br J Dermatol 2019 12 27;181(6):1331-1332. Epub 2019 Aug 27.

Department of Dermatology, Henry Ford Hospital, Detroit, Michigan, U.S.A.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjd.18263DOI Listing
December 2019
5 Reads

Recessive mosaicism in ABCA12 causes blaschkoid congenital ichthyosiform erythroderma.

Br J Dermatol 2020 01 28;182(1):208-211. Epub 2019 Jul 28.

Department of Dermatology, Maastricht University Medical Center, Maastricht, the Netherlands.

We report the unique case of a 3-year-old girl who presented with linear erythematosquamous lesions following the lines of Blaschko, suggestive of genetic mosaicism in the skin. Single-candidate gene analyses were performed on DNA from blood, excluding Conradi-Hünermann-Happle syndrome, erythrokeratodermia variabilis and a mosaic presentation of pityriasis rubra pilaris. With whole-exome sequencing (WES) on DNA from the patient's blood, a heterozygous missense mutation in exon 25 of the ABCA12 gene was detected. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjd.18216DOI Listing
January 2020
8 Reads

Using Neural Networks for Diagnosing in Dermatology.

Stud Health Technol Inform 2019 ;261:211-216

ITMO University, Saint-Petersburg, Russia.

The paper deals with neural networks for decision support in diagnosing in dermatology. There were several iterations during development. We classified six diseases using ANN: (1) Psoriasis, (2) Seborrheic dermatitis, (3) Lichen planus, (4) Pityriasis rosea, (5) Cronic dermatitis, (6) Pityriasis rubra pilaris. Read More

View Article

Download full-text PDF

Source
September 2019
8 Reads

Pityriasis rubra pilaris.

Presse Med 2019 Jun 26;48(6):730-731. Epub 2019 May 26.

Habib Thameur hospital, dermatology department, 1008 Tunis, Tunisia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.lpm.2019.05.009DOI Listing
June 2019
18 Reads

Squamous cell carcinoma antigen is useful in the differential diagnosis of erythroderma.

Int J Dermatol 2019 Aug 20;58(8):e158-e159. Epub 2019 May 20.

Department of Dermatology, Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ijd.14498DOI Listing
August 2019
1 Read

Lokalisierte Pityriasis rubra pilaris in der Schwangerschaft: Eine sehr seltene Sonderform mit therapeutischer Herausforderung.

J Dtsch Dermatol Ges 2019 May;17 Suppl 2:28-30

Klinik und Poliklinik für Dermatologie und Allergologie, Universitätsklinikum der Rheinischen Friedrich-Wilhelms-Universität Bonn.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ddg.13787DOI Listing
May 2019
7 Reads